Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Lubenow

Interventional Pain Medicine Chicago, IL Medical Doctor

NPI 1922024470 CMS profile 132906

1653 W Congress Pkwy, 735 Jelke Anesthesia Department, Chicago, IL 60612

Open in the dashboard

General payments

$556,153

1,507 records reported · program years 2019–2025

Research payments

$1,000

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$299,604 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Timothy Lubenow of Chicago, IL is reported in the CMS Open Payments database as having received $556,153 across 1,507 general payments and $1,000 in research payments paid to them. Separately, studies naming them as principal investigator received $299,604 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,438 132
2024 General $37,190 190
2023 General $105,266 268
2022 General $73,814 237
2021 General $71,579 230
2021 Research $1,000 2
2020 General $101,766 220
2019 General $139,100 230

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Lubenow
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Timothy Lubenow were reported at $27,438. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Timothy Lubenow Interventional Pain Medicine median Middle half National median
2019 $139,100 $684 $216–$2,079 $163
2020 $101,766 $382 $122–$1,109 $114
2021 $71,579 $552 $167–$1,554 $132
2022 $73,814 $605 $187–$1,924 $149
2023 $105,266 $671 $195–$1,915 $160
2024 $37,190 $684 $206–$1,837 $164
2025 $27,438 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $245,739 902 payments
  2. Boston Scientific Corporation $160,106 195 payments
  3. Nevro Corp. $69,298 146 payments
  4. Vertiflex, Inc. $26,978 44 payments
  5. BIOTRONIK NRO, Inc. $14,975 45 payments
  6. AbbVie, Inc. $7,722 46 payments
  7. Painteq LLC $7,334 14 payments
  8. Medtronic, Inc. $6,486 18 payments
  9. Flowonix Medical Incorporated $5,506 1 payment
  10. Medtronic USA, Inc. $4,424 8 payments
  11. Other $7,585 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $237,329 89 payments
  2. Consulting Fee $108,419 61 payments
  3. Food and Beverage $59,896 1,130 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $53,365 31 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $47,668 37 payments
  6. Travel and Lodging $47,531 156 payments
  7. Education $1,946 3 payments
Products named General payments · program years 2019–2025
  1. Neuromodulation Dspsbls and Accs $77,604 70 payments
  2. PROCLAIM Neuromodulation $58,260 225 payments
  3. Senza Spinal Cord Stimulation System $46,602 88 payments
  4. Superion $30,160 27 payments
  5. Proclaim Family of SCS IPGs $29,802 162 payments
  6. PROCLAIM Neuromodulation $29,218 97 payments
  7. Superion Indirect Decompression System $29,093 38 payments
  8. Superion ISS $26,978 44 payments
  9. Omnia $21,551 43 payments
  10. PROCLAIM Structural Heart $13,577 17 payments
  11. Other $150,028 681 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Nevro Corp. $1,000 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

4,873

Median for Anesthesiology: 322

Drug cost

$144,701

Median for Anesthesiology: $8,738

Branded share of claims

24.9%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 681 $19,890
Ms Contin Morphine Sulfate Brand 18 $18,368
Movantik Naloxegol Oxalate Brand 35 $14,304
Pregabalin Generic 383 $9,372
Oxycodone Hcl Generic 225 $6,756
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 150 $6,101
Fentanyl Generic 79 $5,633
Morphine Sulfate Er Morphine Sulfate Brand 194 $5,507
Oxycontin Oxycodone Hcl Brand 18 $5,048
Gabapentin Generic 301 $4,945

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$150,956

Of which drugs: $264

Medicare patients

398

Average age 69

Services billed

2,954

257 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 32%
Ischemic heart disease 31%
Diabetes 28%
Chronic kidney disease 23%
Osteoporosis 23%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 26 1,360 $113

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Prialt
$136 — —
NURTEC ODT
$61 — —
XTAMPZA
$29 — —
UBRELVY
$22 — —
QULIPTA
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

1,509 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record